Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Chris Boylan who wrote (9048)	3/9/1999 9:19:00 PM
From: aknahow	Respond to of 17367

"If you accept this at face value and interpret it literally it supports the enrolling too many healthy people argument and I think that's the best we can hope for at the moment." The sickness factor is probably not correct. The Glascow scale has been in use for ages and given the clinical conditions presented by meningococcemia there is a good agreement on the state of the patients. Eight is not a low " too healthy" number. "........doesn't it seem like the most logical explanation is that the mortality efficacy is bumping along between the target p value and chance?" No, I have no doubt various DSMBs would say stop the trial as the results are not statistically significant. So not stopping means something worthwhile is being seen but XOMA would logically be afraid to halt the trial before reaching a target it had already agreed to with the FDA, when it has no way of knowing just how significant this :something" is.